Pemazyre 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
amended 
on 
PSUSA/10923
Periodic Safety Update EU Single assessment - 
25/05/2023 
26/07/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202210 
pemigatinib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10923/202210. 
IA/0011 
A.5.b - Administrative change - Change in the name 
24/03/2023 
n/a 
and/or address of a manufacturer/importer of the 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
PSUSA/10923
Periodic Safety Update EU Single assessment - 
15/12/2022 
24/02/2023 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
/202204 
pemigatinib 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10923/202204. 
R/0007 
Renewal of the marketing authorisation. 
15/12/2022 
23/02/2023 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Pemazyre, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
IB/0009/G 
This was an application for a group of variations. 
02/12/2022 
23/02/2023 
SmPC 
B.II.d.2.d - Change in test procedure for the finished 
product - Other changes to a test procedure 
(including replacement or addition) 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.d.2.a - Change in test procedure for the finished 
Page 2/5 
 
 
 
 
 
 
 
 
 
 
 
product - Minor changes to an approved test 
procedure 
IB/0008/G 
This was an application for a group of variations. 
01/12/2022 
n/a 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.d.1.z - Stability of AS - Change in the re-test 
period/storage period or storage conditions - Other 
variation 
B.I.b.1.b - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Tightening of 
specification limits 
B.I.b.2.a - Change in test procedure for AS or 
starting material/reagent/intermediate - Minor 
changes to an approved test procedure 
Page 3/5 
 
 
 
 
 
 
 
 
 
PSUSA/10923
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
/202110 
pemigatinib 
II/0005 
Update of sections 4.4, 4.8 and 5.1 of the SmPC 
19/05/2022 
23/02/2023 
SmPC and 
The main proposed changes in the SmPC are as follows: 
based on the final results from study INCB054828 
Annex II 
- 
Section 4.4: update of data on Hyperphosphatemia 
(FIGHT-202) listed as a specific obligation in the 
Annex II (SOB/002); this is a phase 2 study 
investigating the efficacy and safety of pemigatinib in 
adults with advanced/metastatic or surgically 
unresectable cholangiocarcinoma including FGFR2 
translocations who failed previous therapy. The 
Annex II has been updated accordingly. RMP version 
2.0 has also been submitted. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
and Hypophosphatemia based on INCB 54828-202 final 
CSR 
- 
Section 4.8: update of frequency of AEs and 
description of Hyperphosphatemia and Serious retinal 
detachment based on INCB 54828-202 final CSR 
- 
Section 5.1: update of efficacy results based on 
INCB 54828-202 final CSR 
For more information, please refer to the Summary of 
Product Characteristics. 
R/0003 
Renewal of the marketing authorisation. 
16/12/2021 
16/02/2022 
SmPC and PL 
The CHMP, having reviewed the available information on 
the status of the fulfilment of Specific Obligations and 
having confirmed the positive benefit risk balance, is of the 
opinion that the quality, safety and efficacy of this 
medicinal product continue to be adequately and 
sufficiently demonstrated and therefore recommends the 
renewal of the conditional MA for Pemazyre, subject to the 
Specific Obligations and Conditions as laid down in Annex II 
to the opinion. 
PSUSA/10923
Periodic Safety Update EU Single assessment - 
02/12/2021 
n/a 
PRAC Recommendation - maintenance 
/202104 
pemigatinib 
Page 4/5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0001 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
03/08/2021 
16/02/2022 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
Page 5/5 
 
 
 
 
 
 
 
 
